1 active not recruiting, 1 completed, 1 no longer available, 1 unknown. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Oblato, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID - High-grade Glioma, Oligodendroglioma | Phase 1 | Active not recruiting | Oblato, Inc. | 16 | 2023-04-17 | 2024-11-29 |
| Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants OKN-007 - Glioblastoma, Astrocytoma | Phase 1 / Phase 2 | Withdrawn | Oblato, Inc. | 2022-08-01 | 2022-10-07 | |
| Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma OKN-007, Temozolomide (TMZ) - Recurrent Malignant Glioma, Brain Glioblastoma | Phase 2 | Completed | Oblato, Inc. | 57 | 2020-06-12 | 2025-08-12 |
| Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients OKN-007 - Recurrent Malignant Glioma | Phase 1 | Unknown | Oblato, Inc. | 31 | 2012-12-01 | 2023-03-29 |
| Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered OKN-007 - Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | No longer available | Oblato, Inc. | 2024-11-08 |
Glioma (4) · Astrocytoma (2) · Glioblastoma (2) · Oligodendroglioma (2) · Diffuse Intrinsic Pontine Glioma (1)
OKN 007 (5) · BID protein, human (1) · Temozolomide (1) · disufenton sodium (1)
United States (4)